{
    "name": "perampanel",
    "comment": "Rx",
    "other_names": [
        "Fycompa"
    ],
    "classes": [
        "Anticonvulsants",
        "AMPA Glutamate Antagonists"
    ],
    "source": "https://reference.medscape.com/drug/fycompa-perampanel-999784",
    "pregnancy": {
        "common": [
            "There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antiepileptic drugs (AEDs); encourage women to enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry by calling 1-888-233-2334 or visiting http://www.aedpregnancyregistry.org",
            "There are no adequate data on the developmental risk associated with use in pregnant women; in animal studies, perampanel induced developmental toxicity in pregnant rat and rabbit at clinically relevant doses"
        ],
        "specific": [
            {
                "type": "Contraception",
                "description": [
                    "Advise women who are using a levonorgestrel-containing contraceptive to use an additional non-hormonal form (eg, condoms) of contraception while in therapy and for a month after discontinuation"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Perampanel and/or its metabolites are present in rat milk, and are detected at concentrations higher than that in maternal plasma",
            "The developmental and health benefits of breastfeeding should be considered along with the motherâ€™s clinical need for therapy and any potential adverse effects on the breastfed child from therapy or from the underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [
                "Serious or life-threatening psychiatric and behavioral adverse reactions including aggression, hostility, irritability, anger, and homicidal ideation, and threats reported",
                "May occur with and without prior psychiatric history, prior aggressive behavior, or concomitant use of medications associated with hostility and aggression",
                "Advise patients and caregivers to contact a healthcare provider immediately if any of these reactions or changes in mood, behavior, or personality that are not typical for the patient are observed",
                "Closely monitor patients particularly during the titration period and at higher doses",
                "Reduce dose if psychiatric and behavioral reactions occur and discontinue if symptoms are severe or worsen"
            ],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [],
            "specific": [
                {
                    "type": "Serious psychiatric and behavioral reactions",
                    "description": [
                        "Aggression-related adverse reactions reported at doses of 8 mg and 12 mg per day, these effects were dose-related and generally appeared within first 6 weeks of treatment, although new events continued to be observed through more than 37 weeks",
                        "Other symptoms included belligerence, affect lability, agitation, and physical assault; some events were reported as serious and life-threatening; homicidal ideation and/or threat also reported postmarketing",
                        " These events occurred in patients with and without prior psychiatric history, prior aggressive behavior, or concomitant use of medications associated with hostility and aggression",
                        "Some patients experienced worsening of their pre-existing psychiatric conditions; patients with active psychotic disorders and unstable recurrent affective disorders have not been studied",
                        "Combination with alcohol significantly worsened mood and increased anger; patients receiving therapy should avoid use of alcohol",
                        "Similar serious psychiatric and behavioral events also reported in patients with primary generalized tonic-clonic seizure; psychiatric events included paranoia, euphoric mood, agitation, anger,mental status changes, and disorientation/confusional state",
                        "in the postmarketing setting, there have also been reports of psychosis (acute psychosis, hallucinations, delusions, paranoia)and delirium (delirium, confusional state, disorientation, memory impairment) in patients receiving therapy",
                        "Patients, their caregivers, and families should be informed that the drug may increase risk of psychiatric events; patients should be monitored during treatment and for at least 1 month after last dose, and especially when taking higher doses and during initial few weeks of drug therapy (titration period) or at other times of dose increases; dose should be reduced if these symptoms occur",
                        "Permanently discontinue therapy for persistent severe or worsening psychiatric symptoms or behaviors and refer for psychiatric evaluation"
                    ]
                },
                {
                    "type": "Suicidal behavior and ideation",
                    "description": [
                        "Antiepileptic drugs (AEDs) increase risk of suicidal thoughts or behavior in patients taking these drugs for any indication; patients treated with any AED for any indication should be monitored for emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior",
                        "The increased risk of suicidal thoughts or behavior with AEDs reported as early as 1 week after starting drug treatment with AEDs and persisted for duration of treatment assessed; because assessment did not extend beyond 24 weeks, the risk of suicidal thoughts or behavior beyond 24 weeks could not be determined",
                        "Anyone considering prescribing this drug or any other AED must balance risk of suicidal thoughts or behavior with risk of untreated illness; epilepsy and many other illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior; should suicidal thoughts and behavior emerge during treatment, the prescriber needs to consider whether the emergence of these symptoms in any given patient may be related to illness being treated"
                    ]
                },
                {
                    "type": "Neurologic effects",
                    "description": [
                        "Dose-related increases in dizziness and disturbance in gait or coordination reported among patients with partial-onset seizure; these adverse reactions also observed in patients with primary generalized tonic-clonic seizures",
                        "Dose-dependent increases in somnolence and fatigue-related events (including fatigue, asthenia, and lethargy) also reported; adverse reactions occurred mostly during titration phase; also reported with primary generalized tonic-clonic seizures",
                        "An increased risk of falls, in some cases leading to serious injuries including head injuries and bone fracture, reported in patients being treated with this drug (with and without concurrent seizures); elderly patients reported to have increased risk of falls compared to younger adults and pediatric patients",
                        "Prescribers should advise patients against engaging in hazardous activities requiring mental alertness, such as operating motor vehicles or dangerous machinery, until effect known; patients should be carefully observed for signs of central nervous system (CNS) depression, such as somnolence and sedation, when drug is used with other drugs with sedative properties because of potential additive effect"
                    ]
                },
                {
                    "type": "Drug reaction with eosinophilia and systemic symptoms (DRESS)",
                    "description": [
                        "Also known as multiorgan hypersensitivity, DRESS has been reported in patients receiving therapy; DRESS may be fatal or life-threatening; DRESS typically, although not exclusively, presents with fever, rash, lymphadenopathy, and/or facial swelling, in association with other organ system involvement, such as hepatitis, nephritis, hematological abnormalities, myocarditis, or myositis sometimes resembling an acute viral infection; eosinophilia is often present",
                        "Because this disorder is variable in its expression, other organ systems not noted here may be involved; important to note that early manifestations of hypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not evident; if such signs or symptoms are present, the patient should be evaluated immediately",
                        "Therapy should be discontinued if an alternative etiology for signs or symptoms cannot be established"
                    ]
                },
                {
                    "type": "Withdrawal of antiepileptic drugs",
                    "description": [
                        "There is potential of increased seizure frequency in patients with seizure disorders when antiepileptic drugs are withdrawn abruptly; this drug has a half-life of approximately 105 hours so that even after abrupt cessation, blood levels fall gradually; in epilepsy clinical trials was withdrawn without down-titration; although a small number of patients exhibited seizures following discontinuation, the data were not sufficient to allow any recommendations regarding appropriate withdrawal regimens",
                        "A gradual withdrawal is generally recommended with antiepileptic drugs, but if withdrawal is a response to adverse events, prompt withdrawal can be considered"
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Moderate to strong CYP3A4 inducers (eg, carbamazepine, oxcarbazepine, phenytoin, phenobarbital, primidone, topiramate) may greatly increase clearance, resulting in reduced perampanel plasma concentrations (see Dosage Modifications)"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Dizziness",
            "percent": "16-43"
        },
        {
            "name": "Somnolence",
            "percent": "9-18"
        },
        {
            "name": "Headache",
            "percent": "11-13"
        },
        {
            "name": "Fatigue",
            "percent": "8-12"
        },
        {
            "name": "Irritability",
            "percent": "4-12"
        },
        {
            "name": "Falls",
            "percent": "2-10"
        },
        {
            "name": "Nausea",
            "percent": "6-8"
        },
        {
            "name": "Ataxia",
            "percent": "1-8"
        },
        {
            "name": "Vertigo",
            "percent": "3-5"
        },
        {
            "name": "Balance disorder",
            "percent": "3-5"
        },
        {
            "name": "Back pain",
            "percent": "2-5"
        },
        {
            "name": "Weight gain",
            "percent": "4"
        },
        {
            "name": "Vomiting",
            "percent": "2-4"
        },
        {
            "name": "Anxiety",
            "percent": "3-4"
        },
        {
            "name": "Blurred vision",
            "percent": "1-4"
        },
        {
            "name": "Dysarthria",
            "percent": "1-4"
        },
        {
            "name": "Cough",
            "percent": "1-4"
        },
        {
            "name": "Hypoaesthesia",
            "percent": "3"
        },
        {
            "name": "Constipation",
            "percent": "2-3"
        },
        {
            "name": "Arthralgia",
            "percent": "2-3"
        },
        {
            "name": "Extremity pain",
            "percent": "2-3"
        },
        {
            "name": "Aggression",
            "percent": "1-3"
        },
        {
            "name": "Anger",
            "percent": "1-3"
        },
        {
            "name": "Myalgia",
            "percent": "1-3"
        },
        {
            "name": "Diplopia",
            "percent": "1-3"
        },
        {
            "name": "Injuries due to falls",
            "percent": "1-3"
        },
        {
            "name": "Hypersomnia",
            "percent": "1-3"
        },
        {
            "name": "Hyponatremia",
            "percent": "2"
        },
        {
            "name": "Contusions",
            "percent": "2"
        },
        {
            "name": "Oropharyngeal pain",
            "percent": "2"
        },
        {
            "name": "Asthenia",
            "percent": "1-2"
        },
        {
            "name": "Confusional state",
            "percent": "1-2"
        },
        {
            "name": "Euphoric mood",
            "percent": "1-2"
        },
        {
            "name": "Altered mood",
            "percent": "1-2"
        },
        {
            "name": "Abnormal coordination",
            "percent": "1-2"
        },
        {
            "name": "Musculoskeletal pain",
            "percent": "1-2"
        },
        {
            "name": "Peripheral edema",
            "percent": "1-2"
        },
        {
            "name": "Memory impairment",
            "percent": "1-2"
        },
        {
            "name": "Paraesthesia",
            "percent": "1-2"
        },
        {
            "name": "Acute psychosis",
            "percent": null
        },
        {
            "name": "hallucinations",
            "percent": null
        },
        {
            "name": "delusions",
            "percent": null
        },
        {
            "name": "paranoia",
            "percent": null
        },
        {
            "name": "delirium",
            "percent": null
        },
        {
            "name": "disorientation",
            "percent": null
        },
        {
            "name": "drug reaction with eosinophilia and systemic symptoms",
            "percent": null
        },
        {
            "name": "DRESS",
            "percent": null
        },
        {
            "name": "multiorgan hypersensitivity",
            "percent": null
        }
    ]
}